Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1617srh
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload

NEWS EXPRESS April 18 CURRENT WINDOWS VERSION IS V6.0,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 04/06

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:12:48 ON 10 MAY 2001

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	0.30

FILE 'REGISTRY' ENTERED AT 10:13:59 ON 10 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 9 MAY 2001 HIGHEST RN 335078-44-9
DICTIONARY FILE UPDATES: 9 MAY 2001 HIGHEST RN 335078-44-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> s misoprostol/cn
L1 1 MISOPROSTOL/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 59122-46-2 REGISTRY
CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11.alpha.,13E)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Cytotec
CN Misoprostil
CN **Misoprostol**
CN SC 29333
FS STEREOSEARCH
DR 62015-39-8, 143913-16-0, 92999-98-9
MF C22 H38 O5
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IMSDIRECTORY, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, RTECS*, SYNTHLINE, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.
Double bond geometry as shown.



711 REFERENCES IN FILE CA (1967 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
711 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s cyclodextrin/cn
L2 1 CYCLODEXTRIN/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 12619-70-4 REGISTRY
CN **Cyclodextrin (9CI)** (CA INDEX NAME)
OTHER NAMES:

CN Celdex
CN Celdex CH 20
CN Celdex CH 30
CN Celdex SH 20
CN Celdex SH 40
CN Cycloamylose
CN Rhodocap L 20
CN Ringdex P
DR 100091-36-9
MF Unspecified
CI COM, MAN
LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, NAPRALERT, PIRA, PROMT, TOXLINE, TOXLIT, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
3009 REFERENCES IN FILE CA (1967 TO DATE)
966 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3015 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s alprostadil/cn
L3 1 ALPROSTADIL/CN

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 745-65-3 REGISTRY
CN Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13E,15S)-(9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)-
(8CI)
CN Cyclopentaneheptanoic acid, 3.alpha.-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-
(7CI)
OTHER NAMES:
CN (-)-Prostaglandin E1
CN 11.alpha.,15(S)-Dihydroxy-9-oxo-13-trans-prostenoic acid
CN 11.alpha.,15.alpha.-Dihydroxy-9-oxo-13-trans-prostenoic acid
CN **Alprostadil**
CN Alprox TD
CN Caverject
CN l-PGE1
CN l-Prostaglandin E1
CN PGE1
CN Prostaglandin E1
CN Prostandin
CN Prostandin 500
CN U 10136
FS STEREOSEARCH
DR 50-83-9, 22299-37-2, 50865-30-0
MF C20 H34 O5
CI COM
LC STN Files: ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB,

IMSDIRECTORY, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.
Double bond geometry as shown.



8176 REFERENCES IN FILE CA (1967 TO DATE)
136 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8179 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.83	17.13

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, ...' ENTERED AT 10:15:44 ON 10 MAY 2001

59 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s (l1 or misoprostol or cytotec or Misoprostil) and (l3 or alprostadil or Prostaglandin E1 or PGE1 or Prostandin)
'E1' NOT FOUND
The E# entered is not currently defined.

=> s (l1 or misoprostol or cytotec or Misoprostil) and (l3 or alprostadil or Prostaglandin E or PGE1 or Prostandin)

66*	FILE ADISALERTS
6	FILE ADISINSIGHT
1	FILE AGRICOLA
0*	FILE AQUASCI
2	FILE BIOBUSINESS
0*	FILE BIOCOMMERCE
384	FILE BIOSIS
40	FILE BIOTECHNO
3*	FILE CABA
35	FILE CANCERLIT

13 FILES SEARCHED...

```
      223*  FILE CAPLUS
        0*  FILE CEABA-VTB
        3*  FILE CONFSCI
        0*  FILE CROPB
        0*  FILE CROPU
        0*  FILE DDFB
      187*  FILE DDFU
        0*  FILE DGENE
  23 FILES SEARCHED...
        0*  FILE DRUGB
      231*  FILE DRUGU
        2   FILE DRUGUPDATES
        0*  FILE EMBAL
      223   FILE EMBASE
       77*  FILE ESBIOBASE
  32 FILES SEARCHED...
        0*  FILE FOMAD
        0*  FILE FOREGE
        0*  FILE FROSTI
        0*  FILE GENBANK
        0*  FILE HEALSAFE
        7*  FILE IFIPAT
        5   FILE JICST-EPLUS
  40 FILES SEARCHED...
        0*  FILE KOSMET
       30*  FILE LIFESCI
        0*  FILE MEDICONF
      510   FILE MEDLINE
        1*  FILE NTIS
        0*  FILE OCEAN
  47 FILES SEARCHED...
      140*  FILE PASCAL
        5   FILE PHAR
        0*  FILE PHIC
       11*  FILE PHIN
        9   FILE PROMT
      291*  FILE SCISEARCH
        1   FILE SYNTHLINE
      241   FILE TOXLINE
  55 FILES SEARCHED...
      149   FILE TOXLIT
       94*  FILE USPATFULL
       11   FILE WPIDS
       11   FILE WPINDEX

  31 FILES HAVE ONE OR MORE ANSWERS,   59 FILES SEARCHED IN STNINDEX

L4   QUE (L1 OR MISOPROSTOL OR CYTOTEC OR  MISOPROSTIL) AND (L3 OR
ALPROSTADIL
        OR PROSTAGLANDIN E OR PGE1 OR PROSTANDIN)

=> d rank
F1          510   MEDLINE
F2          384   BIOSIS
F3          291*  SCISEARCH
F4          241   TOXLINE
F5          231*  DRUGU
F6          223   EMBASE
F7          223*  CAPLUS
F8          187*  DDFU
F9          149   TOXLIT
```

```
F10         140*  PASCAL
F11          94*  USPATFULL
F12          77*  ESBIOBASE
F13          66*  ADISALERTS
F14          40   BIOTECHNO
F15          35   CANCERLIT
F16          30*  LIFESCI
F17          11   WPIDS
F18          11   WPINDEX
F19          11*  PHIN
F20           9   PROMT
F21           7*  IFIPAT
F22           6   ADISINSIGHT
F23           5   JICST-EPLUS
F24           5   PHAR
F25           3*  CABA
F26           3*  CONFSCI
F27           2   BIOBUSINESS
F28           2   DRUGUPDATES
F29           1   AGRICOLA
F30           1   SYNTHLINE
F31           1*  NTIS


=> file f1-f19
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               3.60      20.73

FILE 'MEDLINE' ENTERED AT 10:20:32 ON 10 MAY 2001

FILE 'BIOSIS' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'SCISEARCH' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'TOXLINE' ENTERED AT 10:20:32 ON 10 MAY 2001

FILE 'DRUGU' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.

FILE 'CAPLUS' ENTERED AT 10:20:32 ON 10 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'TOXLIT' ENTERED AT 10:20:32 ON 10 MAY 2001

FILE 'PASCAL' ENTERED AT 10:20:32 ON 10 MAY 2001
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2001 INIST-CNRS. All rights reserved.

FILE 'USPATFULL' ENTERED AT 10:20:32 ON 10 MAY 2001
```

CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ESBIOBASE' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ADISALERTS' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Adis International Ltd. (ADIS)

FILE 'BIOTECHNO' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 10:20:32 ON 10 MAY 2001

FILE 'LIFESCI' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'PHIN' ENTERED AT 10:20:32 ON 10 MAY 2001
COPYRIGHT (C) 2001 PJB Publications Ltd. (PJB)

=> s l4
'CN' IS NOT A VALID FIELD CODE
   5 FILES SEARCHED...
'CN' IS NOT A VALID FIELD CODE
'CN' IS NOT A VALID FIELD CODE
  13 FILES SEARCHED...
'CN' IS NOT A VALID FIELD CODE
L5   2966 L4

=> s female sexual? dysfunction
  13 FILES SEARCHED...
L6   705 FEMALE SEXUAL? DYSFUNCTION

=> s l5 and l6
L7   3 L5 AND L6

=> d ti

L7   ANSWER 1 OF 3 USPATFULL
TI   Compositions

=> d 2-3 ti

L7   ANSWER 2 OF 3 USPATFULL
TI   Compositions

L7   ANSWER 3 OF 3 USPATFULL
TI   Compositions

=> d ibib abs kwic tot

L7   ANSWER 1 OF 3 USPATFULL
ACCESSION NUMBER: 1999:110350 USPATFULL
TITLE: Compositions

INVENTOR(S):	Dias Nahoum, Cesar Roberto, P.O. Box 1539, King of Prussia, PA, United States 19406-0939

	NUMBER	DATE
PATENT INFORMATION:	US 5952361	19990914
APPLICATION INFO.:	US 1998-37097	19980309 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-444130, filed on 18 May 1995, now patented, Pat. No. US 5773457 which is a continuation of Ser. No. US 1995-381945, filed on 15 Feb 1995	

	NUMBER	DATE
PRIORITY INFORMATION:	BR 1992-3277	19920821

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Reamer, James H.
LEGAL REPRESENTATIVE:	Dinner, Dara L.; Venetianer, Stephen; Kinzig, Charles M.
NUMBER OF CLAIMS:	34
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	1524

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the novel use of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction.**

SUMM In 1986, Ishii et al injected for the first time **prostaglandin E**.sub.1 into human corpora cavernosa for the treatment of organic impotence, Ishii, N. et al. "Therapeutic trial with **prostaglandin E**.sub.1 for organic impotence". Jap. J. Imp., 1: 54-962 (1986). See also Ishii, N. et al "Intracavernous injection of **prostaglandin E**.sub.1 for the treatment of erectile impotence". J. Urol., 141(2): 323-325 (1989). Since it is a drug of natural occurrence in. . .

SUMM . . . following the use of such a combination, von-Heyden et al. J. Urol., 149(5 Pt 2): 1288-1290 (1993). The use of **prostaglandin E**.sub.1 is often rejected by patients because of the painfulness of its injection. Waldhauser, M. et al., J. Urol., 140(3): 525-527. . .

SUMM . . . Impotence Res., 4(Suppl. 2): A91 (1992)) compared the erectogenic efficiency of 1 mg of SIN-1 (Linsindomin-Corvasal.RTM.) against 20 .mu.g of **PGE1** (Prostavasin.RTM.), both of them administered by intracavernous vias to 40 consecutive patient complaining of erectile failure. According to the latter author: ". . . SIN-1 is considerably less effective than **PGE1** and will therefore, not play a major role in the management of male impotence".

SUMM . . . pharmaceutical composition of an H.sub.2 receptor agonist and a pharmaceutically acceptable carrier or diluent in the treatment of male and **female sexual dysfunction** or impotence. A preferred pharmaceutical composition for use herein comprises the H.sub.2 agonist, N-[2-(5-Methyl-4-imidazolyl)methyl-thio)ethyl]-N'-[3-(4-imidazolyl)propyl]-guanidine) and pharmaceutically acceptable salts thereof (herein. . .

SUMM Another aspect of the present invention for treatment of male and **female sexual dysfunction** in a animal, including human beings is the use in such treatment of an H.sub.3 agonist, or a pharmaceutical composition. . .

SUMM . . . are not limited to, paracrine mediators such as prostaglandins and analogs thereof having vasoactive functions, such as PGE.sub.1 and PGE.sub.2, **alprostadil** and **misoprostol**; histamine; peptides such as calcitonin gene related peptides (CGRP) or vasoactive intestinal peptide (VIP); calcium antagonists or blockers, such as. . .

SUMM As used herein "sexual dysfunction" refers to both male and **female sexual dysfunctions**, and includes for women organic dysfunctions related to clitoridal disturbances.

CLM What is claimed is:
27. A method of treating **female sexual dysfunction** in a human in need thereof which method comprises administering to said human an effective amount of an H.sub.2 agonist.
. . .

IT 50-60-2, Phentolamine 51-45-6, Histamine, biological studies 57-47-6, Physostigmine 58-74-2, Papaverine 59-96-1, Phenoxybenzamine 59-99-4, Neostigmine 86-54-4, Hydralazine **745-65-3**, PGE1 14402-89-2, Sodium nitroprusside 15676-16-1, Sulpiride 37221-79-7, VIP 83652-28-2, CGRP
(erectogenic H2 histamine agonist in combination with, for treatment of sexual dysfunction)

L7 ANSWER 2 OF 3 USPATFULL

ACCESSION NUMBER:	1999:63326 USPATFULL
TITLE:	Compositions
INVENTOR(S):	Nahoum, Cesar Roberto Dias, SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
PATENT ASSIGNEE(S):	Nahoum, Cesar Roberto Dias, Rio de Janeiro, Brazil (non-U.S. individual)

	NUMBER	DATE	
PATENT INFORMATION:	US 5908853	19990601	
	WO 9404120	19940303	
APPLICATION INFO.:	US 1995-381945	19950215	(8)
	WO 1993-BR27	19930818	
		19950215	PCT 371 date
		19950215	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	BR 1992-3277	19920821

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Harrison, Robert H.
LEGAL REPRESENTATIVE:	Dinner, Dara L.; Venetianer, Stephen
NUMBER OF CLAIMS:	26
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	1523

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the novel use of H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction** in an animal,

including humans. The H.sub.2 and H.sub.3 agonists may be administered by intracavernousm injection, topically, transdermally, or intraurethrally. The method of use may also include a second therapeutic agent which either facilitates, potentiates or is erectogenic. The second agent may be administered sequentially or contemporaneously with either the H.sub.2 or H.sub.3 agonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . present invention involves the novel use of H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction** in an animal, including humans. The H.sub.2 and H.sub.3 agonists may be administered by intracavernousm injection, topically, transdermally, or intraurethrally.. . .

SUMM In 1986, Ishii et al injected for the first time **prostaglandin E**.sub.1 into human corpora cavernosa for the treatment of organic impotence, Ishii, N. et al. "Therapeutic trial with **prostaglandin E**.sub.1 for organic impotence". Jap. J. Imp., 1: 54-962 (1986). See also Ishii, N. et al "Intracavernous injection of **prostaglandin E**.sub.1 for the treatment of erectile impotence". J. Urol., 141(2): 324-325 (1989). Since it is a drug of natural occurrence in. . .

SUMM . . . following the use of such a combination, von-Heyden et al. J. Urol., 149(5 Pt 2): 1288-1290 (1993). The use of **prostaglandin E**.sub.1 is often rejected by patients because of the painfulness of its injection. Waldhauser, M. et al., J. Urol., 140(3): 525-527. . .

SUMM . . . Impotence Res., 4(Suppl. 2): A91 (1992)) compared the erectogenic efficiency of 1 mg of SIN-1 (Linsindomin-Corvasal.RTM.) against 20 .mu.g of **PGE1** (Porstavasin.RTM.), both of them administered by intracavernous vias to 40 consecutive patient complaining of erectile failure. According to the latter author: " . . . SIN-1 is considerably bless effective than **PGE1** and will therefore, not play a major role in the management of male impotence".

DETD . . . pharmaceutical composition of an H.sub.2 receptor agonist and a pharmaceutically acceptable carrier or diluent in the treatment of male and **female sexual dysfunction** or impotence. A preferred pharmaceutical composition for use herein comprises the H.sub.2 agonist, N-[2-(5-Methyl-4-imidazolyl)methyl-thio)ethyl]-N'-[3-(4-imidazolyl)propyl]-guanidine) and pharmaceutically acceptable salts thereof (herein. . .

DETD Another aspect of the present invention for treatment of male and **female sexual dysfunction** in a animal, including human beings is the use in such treatment of an H.sub.3 agonist, or a pharmaceutical composition. . .

DETD . . . are not limited to, paracrine mediates such as prostaglandins and analogs thereof having vasoactive functions, such as PGE.sub.1 and PGE.sub.2, **alprostadil** and **misoprostol**; histamine; peptides such as calcitonin gene related peptides (CGRP) or vasoactive intestinal peptide (VIP); calcium antagonists or blockers, such as. . .

DETD As used herein "sexual dysfunction" refers to both male and **female sexual dysfunctions**, and includes for women orgasmic dysfunctions related to clitoridal disturbances.

DETD . . . the sequential administration of an H.sub.2 or H.sub.3 agonist and a second therapeutic agent for the treatment of male or **female sexual dysfunction**.

DETD . . . lower doses or multiple co-administered agents. As noted in WO 91/16021 where small intraurethral suppositories are utilized, individual titration of **PGE1** and prozasin were administered in multiple inserts. Similarly the H.sub.2 agonist alone or in combination with a second agent or. . .

DETD If a third agent, such as phentolamine, papaverine, **PGE1** or sulpiride is also administered the resulting dosage of histamine and Impromidine the reduction in doses of the H.sub.2 /H.sub.3. . .

IT 50-60-2, Phentolamine 51-45-6, Histamine, biological studies 57-47-6, Physostigmine 58-74-2, Papaverine 59-96-1, Phenoxybenzamine 59-99-4, Neostigmine 86-54-4, Hydralazine **745-65-3**, PGE1 14402-89-2, Sodium nitroprusside 15676-16-1, Sulpiride 37221-79-7, VIP 83652-28-2, CGRP
(erectogenic H2 histamine agonist in combination with, for treatment of sexual dysfunction)

L7 ANSWER 3 OF 3 USPATFULL

ACCESSION NUMBER: 1998:75603 USPATFULL
TITLE: Compositions
INVENTOR(S): Nahoum, Cesar Roberto Dias, SmithKline Beecham Corporation Corporate Intellectual Property, UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
PATENT ASSIGNEE(S): Nahoum, Cesar Roberto Dias, Rio de Janeiro, Brazil (non-U.S. individual)

	NUMBER	DATE
PATENT INFORMATION:	US 5773457	19980630
APPLICATION INFO.:	US 1995-444130	19950518 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-381945, filed on 15 Feb 1995
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Dinner, Dara L.; Venetianer, Stephen; Lentz, Edward T.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves the novel use of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . . . of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and **female sexual dysfunction**.

SUMM . . . time prustaglandin E.sub.1 into human corpora cavernosa for the treatment of organic impotence, Ishii, N. et al. "Therapeutic trial with **prostaglandin E**.sub.1 for organic impotence". Jap. J. Imp., 1:54-962 (1986). See also Ishii, N. et al "Intracavernous injection of **prostaglandin E**.sub.1 for the treatment of erectile impotence". J. Urol., 141(2):323-325 (1989). Since it is a drug of natural occurrence in the. . .

SUMM . . . reported following the use of such a combination, von-Heyden et

al. J. Urol., 149(5 Pt 2):1288-1290 (1993). The use of **prostaglandin E**.sub.1 is often rejected by patients because of the painfulness of its injection. Waldhauser, M. et al., J. Urol., 140(3):525-527 (1988).

SUMM . . . Impotence Res., 4(Suppl. 2): A91 (1992)) compared the erectogenic efficiency of 1 mg of SIN-1 (Linsindomin-Corvasal.RTM.) against 20 .mu.g of **PGE1** (Prostavasin.RTM.), both of them administered by intracavernous vias to 40 consecutive patient complaining of erectile failure. According to the latter author: ". . . SIN-1 is considerably less effective than **PGE1** and will therefore, not play a major role in the management of male impotence".

DETD . . . pharmaceutical composition of an H.sub.2 receptor agonist and a pharmaceutically acceptable carrier or diluent in the treatment of male and **female sexual dysfunction** or impotence. A preferred pharmaceutical composition for use herein comprises the H.sub.2 agonist, N-[2-(5-Methyl-4-imidazolyl)methyl-thio)ethyl]-N'-[3-(4-imidazolyl)propyl]-guanidine) and pharmaceutically acceptable salts thereof (herein. . .

DETD Another aspect of the present invention for treatment of male and **female sexual dysfunction** in a animal, including human beings is the use in such treatment of an H.sub.3 agonist, or a pharmaceutical composition. . .

DETD . . . are not limited to, paracrine mediators such as prostaglandins and analogs thereof having vasoactive functions, such as PGE.sub.1 and PGE.sub.2, **alprostadil** and **misoprostol**; histamine; peptides such as calcitonin gene related peptides (CGRP) or vasoactive intestinal peptide (VIP); calcium antagonists or blockers, such as. . .

DETD As used herein "sexual dysfunction" refers to both male and **female sexual dysfunctions**, and includes for women orgasmic dysfunctions related to clitoridal disturbances.

DETD . . . the sequential administration of an H.sub.2 or H.sub.3 agonist and a second therapeutic agent for the treatment of male or **female sexual dysfunction.**

DETD . . . lower doses or multiple co-administered agents. As noted in WO 91/16021 where small intraurethral suppositories are utilized, individual titration of **PGE1** and prozasin were administered in multiple inserts. Similarly the H.sub.2 agonist alone or in combination with a second agent or. . .

DETD If a third agent, such as phentolamine, papaverine, **PGE1** or sulpiride is also administered the resulting dosage of histamine and Impromidine the reduction in doses of the H.sub.2 /H.sub.3. . .

IT 50-60-2, Phentolamine 51-45-6, Histamine, biological studies 51-45-6D, Histamine, analogs 57-47-6, Physostigmine 58-74-2, Papaverine 59-33-6 59-96-1, Phenoxybenzamine 59-99-4, Neostigmine 86-54-4, Hydralazine 113-92-8 **745-65-3**, PGE1 14402-89-2, Sodium nitroprusside 15676-16-1, Sulpiride 37221-79-7, Vasoactive intestinal peptide 55273-05-7, Impromidine 65119-89-3, Dimaprit 65573-02-6, Impromidine trihydrochloride 75614-87-8, (R)-.alpha.-Methylhistamine 83652-28-2, Calcitonin gene-related peptide 154962-59-1

(histamine receptor agonists for treatment of erectile dysfunction)

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	39.12	59.85

```
FILE 'STNGUIDE' ENTERED AT 10:26:11 ON 10 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May  4, 2001 (20010504/UP).

=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.00      59.85

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:26:18 ON 10 MAY 2001
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1617srh
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Dec 17  The CA Lexicon available in the CAPLUS and CA files
 NEWS  3  Feb 06  Engineering Information Encompass files have new names
 NEWS  4  Feb 16  TOXLINE no longer being updated
 NEWS  5  Apr 23  Search Derwent WPINDEX by chemical structure
 NEWS  6  Apr 23  PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
 NEWS  7  May 07  DGENE Reload

 NEWS EXPRESS  April 18 CURRENT WINDOWS VERSION IS V6.0,
               CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
               AND CURRENT DISCOVER FILE IS DATED 04/06
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 13:57:31 ON 11 MAY 2001

=> fil medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
```